Diabetes and vascular complications: the role of endothelin and physical inactivity’

Actelion Pharmaceuticals0 个研究点开始时间: 2009年8月21日最近更新: 2012年3月19日

试验速览

暂无简介。

•-Older than 40 years (for both groups)
•-Diagnosed with type 2 diabetes mellitus at least 2 years ago (for the group of type 2 diabetes patients only)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Subjects that use glibenclamide (glyburide), an oral anti-diabetic drug
•-Liver problems (mild, moderate and/or severe liver impairment
•-Increased levels of liver aminotransferase (> 3 times the upper limit of normal)
•-Pregnant or lactating women, women on contraceptive
•-Cardiovascular disease
•-Hypercholesterolemia
•-Hypertension (>160 mmHg systolic and/or >90 mmHg diastolic pressure)
•-Type I diabetes mellitus
•-Older than 65 years
•-Subjects with vascular complications due to type 2 diabetes mellitus (e.g. diabetic foot ulcer)

发起方

Actelion Pharmaceuticals